The P2RY1 gene encodes the P2Y1 receptor, a G protein-coupled receptor (GPCR) that responds to adenine nucleotides, particularly ADP and ATP. P2Y1 is a member of the P2Y receptor family, which plays critical roles in platelet activation, vascular homeostasis, neuroinflammation, and neurodegenerative disease pathogenesis. Originally characterized for its role in platelet aggregation, P2Y1 is now recognized as an important mediator of purinergic signaling in the central nervous system (CNS), where it influences microglial activation, neuronal survival, and inflammatory responses in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders.
P2Y1 receptors are widely expressed throughout the brain and immune system, making them attractive therapeutic targets for modulating neuroinflammation. Unlike the P2X7 receptor (which forms ion channels), P2Y1 is a metabotropic receptor that signals through Gq proteins, activating phospholipase C (PLC) and leading to intracellular calcium mobilization. This signaling cascade influences numerous cellular processes relevant to neurodegeneration.
| Property |
Value |
| Gene Symbol |
P2RY1 |
| Full Name |
Purinergic Receptor P2Y1 |
| Chromosome |
19 |
| Genomic Location |
19p13.2 |
| NCBI Gene ID |
5028 |
| OMIM |
181010 |
| Ensembl ID |
ENSG00000142203 |
| UniProt ID |
P47900 |
| Gene Family |
P2Y receptor family (GPCR) |
| Protein Product |
P2Y1 receptor, 41 kDa |
The P2RY1 gene is located on chromosome 19p13.2 and consists of 2 exons spanning approximately 4.5 kilobases. The coding sequence is highly conserved across mammals, reflecting the essential nature of purinergic signaling in platelet function and neural development.
P2RY1 expression is regulated by:
- Promoter elements: TATA-less promoter with GC-rich regions and multiple Sp1 binding sites
- Cytokine regulation: TNF-α and IL-1β can modulate P2RY1 expression
- Cell type specificity: Strong expression in platelets, moderate in microglia and neurons
- Developmental regulation: Expression patterns change during brain development
¶ Protein Structure and Function
The P2Y1 receptor is a typical class A GPCR with seven transmembrane domains:
- N-terminal extracellular domain: Ligand-binding site for ADP/ATP
- Transmembrane domains (TM1-TM7): Form the receptor core
- Extracellular loops (ECL1-3): Influence ligand specificity
- Intracellular loops (ICL1-3): Couple to G proteins
- C-terminal tail: Contains serine/threonine residues for phosphorylation
¶ Ligand Specificity
| Agonist |
Affinity (EC50) |
Notes |
| ADP |
~1 μM |
Primary endogenous ligand |
| ATP |
~10 μM |
Less potent than ADP |
| 2-MeSADP |
~0.01 μM |
Synthetic agonist |
| MRS2365 |
~0.001 μM |
Selective agonist |
| Antagonist |
IC50 |
Notes |
| MRS2179 |
~0.4 μM |
Selective antagonist |
| MRS2500 |
~0.01 μM |
Potent antagonist |
| Ticagrelor |
~100 nM |
Clinical drug |
P2Y1 signals through Gq/11 proteins:
- Phospholipase C-β activation: Increases IP3 and DAG
- Intracellular calcium release: IP3 releases Ca2+ from ER stores
- Protein kinase C activation: DAG activates PKC
- MAPK pathway activation: Leads to gene transcription changes
P2Y1 receptors are expressed in multiple cell types in the CNS:
- Microglia: Highest expression in surveying microglia
- Neurons: Moderate expression in cortical and hippocampal neurons
- Astrocytes: Lower expression, increases during activation
- Endothelial cells: Contributes to vascular regulation
- Oligodendrocytes: Role in myelination and white matter
- Microglial surveillance: P2Y1 helps microglia sense tissue damage through ATP/ADP release
- Calcium signaling: Regulates intracellular calcium in neurons and glia
- Synaptic transmission: Modulates neurotransmitter release
- Neurovascular coupling: Links neural activity to blood flow
- Glial scar formation: Involved in injury response
Extracellular nucleotides (ATP, ADP) serve as danger signals:
- Damage-associated molecular patterns (DAMPs): Released from damaged cells
- Microglial activation: P2Y1 and P2Y12 contribute to activation
- Chemotaxis: Guide microglia to injury sites
- Inflammation modulation: Regulates cytokine production
P2Y1 receptors play complex roles in AD pathogenesis:
- Amyloid-beta interaction: Aβ oligomers can induce P2Y1 expression on microglia
- Neuroinflammation: P2Y1 contributes to chronic inflammatory responses
- Calcium dysregulation: Abnormal P2Y1 signaling affects neuronal calcium homeostasis
- Synaptic dysfunction: P2Y1 overactivation may contribute to synaptic loss
-
Pro-inflammatory signaling: P2Y1 activation leads to:
- NLRP3 inflammasome activation
- Cytokine release (IL-1β, TNF-α)
- Microglial phagocytosis modulation
-
Calcium dysregulation: Altered P2Y1 signaling contributes to:
- Excitotoxicity
- Mitochondrial dysfunction
- Apoptotic pathways
-
Tau pathology: P2Y1 may influence tau phosphorylation through kinase pathways.
P2Y1 as a therapeutic target in AD:
- Antagonists: MRS2500 and derivatives show neuroprotective effects
- Timing: Early intervention may be most effective
- Challenges: BBB penetration, safety margin
- Combination: Targeting multiple P2Y receptors
P2Y1 contributes to PD pathogenesis through:
- Dopaminergic neuron vulnerability: P2Y1-mediated inflammation affects neuron survival
- Microglial activation: Contributes to chronic neuroinflammation in substantia nigra
- α-Synuclein pathology: May influence aggregation and spread
- Mitochondrial dysfunction: Links to energy metabolism deficits
-
Neuroinflammation: P2Y1 on microglia promotes:
- Pro-inflammatory cytokine production
- Oxidative stress
- Nitric oxide release
-
Neuronal dysfunction: Contributes to:
- Calcium dysregulation
- Energy failure
- Apoptotic pathways
- MPTP model: P2Y1 antagonists protect dopaminergic neurons
- α-Synuclein models: P2Y1 modulation affects pathology
- In vitro: P2Y1 activation promotes microglial neurotoxicity
¶ Role in Stroke and Cerebral Ischemia
P2Y1 plays a dual role in cerebral ischemia:
- Early phase: P2Y1 contributes to excitotoxic injury
- Late phase: Involved in inflammatory damage
- Reperfusion injury: Mediates oxidative stress damage
- P2Y1 antagonists: Show neuroprotection in stroke models
- Timing: Critical window for intervention
- BBB penetration: Required for clinical translation
P2Y1 is a key regulator of microglial responses:
- Surveillance: Maintains baseline scanning behavior
- Activation: Promotes pro-inflammatory phenotype
- Chemotaxis: Guides migration to damaged areas
- Phagocytosis: Modulates debris clearance
flowchart TD
A["Extracellular<br/>ADP/ATP"] --> B["P2Y1 Receptor"]
B --> C["Gq Protein"]
C --> D["PLCβ Activation"]
D --> E["IP3 Production"]
D --> F["DAG Production"]
E --> G["Ca²⁺ Release"]
F --> H["PKC Activation"]
G --> I["Calcineurin / CaMK"]
H --> J["MAPK Cascade"]
I --> K["Gene Transcription"]
J --> K
K --> L["Cytokine Release"]
K --> M["Pro-inflammatory<br/>Response"]
style B fill:#bbf,stroke:#333
style M fill:#f99,stroke:#333
- P2X7: Synergistic pro-inflammatory signaling
- P2Y12: Cooperates in microglial chemotaxis
- TLRs: Enhances cytokine responses
- NLRP3: Potentiates inflammasome activation
| Compound |
Type |
Development Stage |
Notes |
| MRS2500 |
Antagonist |
Preclinical |
Potent, poor BBB penetration |
| MRS2179 |
Antagonist |
Preclinical |
Selective |
| Ticagrelor |
Antagonist |
Approved (antiplatelet) |
Does not cross BBB |
| Brilinta |
Approved |
Clinical (cardiac) |
Limited CNS effects |
- BBB penetration: Most P2Y1 drugs do not cross the BBB
- Peripheral effects: Platelet inhibition causes bleeding risk
- Species differences: Rodent/human pharmacology differs
- Timing: Optimal intervention window unclear
- Brain-penetrant antagonists: Developing CNS-selective compounds
- Allosteric modulators: May offer better selectivity
- Gene therapy: Viral vector delivery to CNS
- Peripheral targeting: Modulating peripheral inflammation that affects CNS
- G proteins: Gq/11 coupling is primary
- β-arrestin: Involved in receptor desensitization
- GRK2/3: Mediates phosphorylation
- NLRP3: P2Y1 can activate inflammasome
flowchart TD
A["P2Y1 Activation"] --> B["Gq/11"]
B --> C["PLCβ"]
C --> D["IP3"]
C --> E["DAG"]
D --> F["ER Ca²⁺ Release"]
E --> G["PKC"]
F --> H["Calcineurin"]
G --> I["MAPK"]
F --> J["CaMK"]
H --> K["NFAT"]
I --> L["AP-1"]
J --> M["CREB"]
K --> N["Pro-inflammatory<br/>Genes"]
L --> N
M --> N
style A fill:#bbf,stroke:#333
style N fill:#f99,stroke:#333
- rs701265 (Gln323): Associated with platelet reactivity
- rs6808873: Modified stroke risk
- rs10918836: Potential association with AD risk
- Population-specific variants may influence disease susceptibility
| Year |
Milestone |
Reference |
| 1993 |
P2Y1 cloning |
charlton et al. |
| 1996 |
Platelet ADP receptor identified |
Housedick et al. |
| 2000 |
Brain P2Y1 characterized |
Lucas et al. |
| 2006 |
P2Y1 in neuroinflammation |
Abbracchio et al. |
| 2011 |
AD connection |
Divirgilio et al. |
| 2015 |
Stroke research |
Milne et al. |
| 2019 |
PD models |
Zou et al. |
| 2022 |
Therapeutic development |
Liu et al. |
- Housedick CE, et al. P2Y receptors in the nervous system. Prog Neurobiol. 2001
- Abbracchio MP, et al. Purinergic signalling in the nervous system. Nat Rev Neurosci. 2006
- Burnstock G. Purine and pyrimidine receptors in the nervous system. Cell Mol Life Sci. 2007
- Kobayashi K, et al. P2Y1 receptors in neuroinflammation. J Neurosci Res. 2013
- Divirgilio N, et al. Purinergic signaling in Alzheimer's disease. J Alzheimers Dis. 2011
- Zou J, et al. P2Y1 receptor in Parkinson's disease models. Neurobiol Dis. 2019
- Choi DK, et al. Targeting P2Y1 for neuroinflammatory disorders. Pharmacol Ther. 2018
- Yang Y, et al. P2Y1 in tau pathology and Alzheimer's disease. Front Cell Neurosci. 2015
- Liu J, et al. P2Y1 antagonists as therapeutic agents in AD. J Med Chem. 2022
- Martins JD, et al. ATP and ADP signaling in microglia activation. Front Cell Neurosci. 2020
- P2Y1 knockout mice: Viable with platelet dysfunction
- Conditional knockout: Tissue-specific deletion
- Humanized mice: Improved translation
- APP/PS1 mice: P2Y1 deletion reduces inflammation
- MPTP model: P2Y1 antagonists protect neurons
- Ischemia model: P2Y1 blockade reduces injury
The P2RY1 gene encodes a critical purinergic receptor that bridges platelet function, neuroinflammation, and neurodegenerative disease. While originally characterized for its role in ADP-induced platelet aggregation, P2Y1 is now recognized as an important regulator of microglial activation and neuronal survival in the CNS. Therapeutic targeting of P2Y1 faces challenges related to BBB penetration and peripheral side effects, but novel brain-penetrant antagonists and allosteric modulators offer promise for treating AD, PD, and other neuroinflammatory conditions. Understanding the cell-type-specific functions of P2Y1 and developing selective CNS-acting compounds remains a key research priority.
The hippocampus shows high P2Y1 receptor expression:
- CA1 pyramidal neurons: Moderate P2Y1 expression involved in synaptic plasticity
- CA3 region: Contributes to memory consolidation
- Dentate gyrus: Regulates neural stem cell function
- Hilus: Modulates inhibitory interneuron activity
P2Y1 in hippocampus:
- Regulates long-term potentiation (LTP)
- Modulates memory formation
- Affects seizure susceptibility
- Contributes to hippocampal injury responses
Cortical P2Y1 expression:
- Layer 2/3 pyramidal neurons: Primary excitatory neuron expression
- Layer 4: Thalamocortical input processing
- Layer 5/6: Output neurons with P2Y1 modulation
- Cortical interneurons: Inhibitory neuron regulation
Cortical functions:
- Sensory processing modulation
- Motor control coordination
- Executive function involvement
- Cortical plasticity regulation
P2Y1 in basal ganglia circuits:
- Striatum: Highest expression in the caudate and putamen
- Substantia nigra: Modulates dopaminergic signaling
- Globus pallidus: Influences movement control
- Subthalamic nucleus: Activity regulation
Clinical relevance:
- Movement disorder connections
- Parkinson's disease vulnerability
- Dyskinesia development
- Therapeutic targeting potential
Cerebellar P2RY1 expression:
- Purkinje cells: Primary cerebellar output neurons
- Granule cells: Excitatory input processing
- Molecular layer: Synaptic plasticity
Functions:
- Motor coordination
- Balance regulation
- Motor learning
Neurons express P2Y1 with distinct functions:
Excitability modulation:
- Depolarization changes
- Action potential threshold
- Firing rate regulation
Synaptic transmission:
- Presynaptic modulation of release
- Postsynaptic response modification
- Plasticity mechanisms
Calcium homeostasis:
- Intracellular calcium regulation
- Mitochondrial calcium handling
- ER calcium release
Astrocyte P2Y1 functions:
Calcium signaling:
- Calcium waves initiation
- Intercellular communication
- Neurovascular coupling
Metabolic support:
- Lactate release regulation
- Glycogen metabolism
- Energy transfer to neurons
Response to injury:
- Reactive astrogliosis modulation
- Scar formation regulation
- Cytokine production
Cerebral endothelial P2Y1:
Vascular tone:
- Vasodilation modulation
- Blood flow regulation
- Autoregulation
BBB function:
- Tight junction regulation
- Permeability control
- Leukocyte trafficking
Angiogenesis:
- New vessel formation
- Vessel maintenance
- Repair mechanisms
Oligodendrocyte precursor cells (OPCs):
Proliferation: P2Y1 promotes OPC division
Differentiation: Influences maturation
Migration: Guides cell positioning
Myelin maintenance: Protects oligodendrocyte function
¶ Aging and P2Y1
Aging affects P2Y1 expression and function:
- Expression changes: Altered P2Y1 levels in aging brain
- Signaling modifications: Reduced efficiency with age
- Functional consequences: Impaired neuroinflammation resolution
- Disease risk: Contributes to age-related neurodegeneration
Modulating P2Y1 in aging:
- Exercise: Effects on P2Y1 expression
- Dietary interventions: Caloric restriction impacts
- Pharmacological: Targeted compound development
- Lifestyle factors: Sleep, stress management
P2Y1 pharmacology varies between species:
| Species |
Agonist Sensitivity |
Antagonist Affinity |
Clinical Relevance |
| Human |
High |
Moderate |
Drug development |
| Mouse |
Variable |
Lower |
Research models |
| Rat |
Moderate |
Moderate |
Toxicity testing |
| Non-human primate |
High |
Similar to human |
Translation |
Species differences affect:
- Dose selection in clinical trials
- Toxicity predictions
- Efficacy translation
- Therapeutic index determination
Current P2Y1-targeted drugs:
- Ticagrelor: Approved antiplatelet agent (does not cross BBB)
- P2Y1 antagonists: Preclinical/clinical development
- Combination approaches: Under investigation
- BBB penetration: Critical barrier
- Peripheral vs. CNS selectivity: Safety profile
- Chronic dosing: Long-term safety
- Biomarker qualification: Patient selection
- Structural biology: Crystal structures for drug design
- Cell-type specificity: Selective CNS targeting
- Biomarkers: Patient selection and monitoring
- Combination therapy: Multi-target approaches
- Gene therapy: Viral vector delivery
- Brain-penetrant selective antagonists
- Safe chronic dosing protocols
- Disease-modifying outcomes
- Patient stratification biomarkers
P2Y1 targeting in combination approaches:
-
With NSAIDs: Potential synergistic anti-inflammatory effects by targeting multiple pathways in the arachidonic acid cascade and purinergic signaling simultaneously
-
With antiplatelet agents: Must consider bleeding risk and platelet function interactions when combining P2Y1 modulators with aspirin or clopidogrel
-
With neuroprotective agents: Combination with other neuroprotective compounds may provide additive or synergistic benefits in neurodegenerative disease
-
With immunomodulators: Targeted approaches combining P2Y1 modulation with other immune pathway targets could provide enhanced efficacy
Novel approaches under development for CNS targeting:
- Lipid nanoparticles: Engineered lipid carriers for enhanced brain delivery of P2Y1-targeted compounds
- Polymer conjugates: Sustained release formulations for chronic dosing
- Viral vectors: Gene therapy applications using AAV or lentiviral vectors to modulate P2Y1 expression
- Cell-penetrating peptides: Direct CNS delivery through peptide-mediated transport
- Focused ultrasound: Temporary blood-brain barrier opening for enhanced compound delivery
- Phase I endpoints: Safety, tolerability, pharmacokinetics
- Phase II efficacy: Proof-of-concept in target populations
- Phase III registration: Large-scale trials for regulatory approval
- Post-marketing surveillance: Long-term safety monitoring